Effect of Conjugated Linoleic Acid on Body Fat in Overweight Children

This study has been completed.
Sponsor:
Collaborator:
Loders Croklaan
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00575991
First received: December 14, 2007
Last updated: March 12, 2012
Last verified: March 2012

December 14, 2007
March 12, 2012
January 2007
June 2008   (final data collection date for primary outcome measure)
body composition using DXA [ Time Frame: 6 months ] [ Designated as safety issue: No ]
body composition using the four-compartment model [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00575991 on ClinicalTrials.gov Archive Site
blood chemistry variables including fasting glucose and insulin, lipids, and liver enzymes [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Effect of Conjugated Linoleic Acid on Body Fat in Overweight Children
Effect of CLA Supplementation on Body Fat Accretion Among Children Who Are Overweight or at Risk of Overweight

The prevalence of overweight children has increased dramatically over the last decade, and many overweight children will remain overweight as adults. Conjugated linoleic acid (CLA), a naturally occurring dietary fatty acid, has shown promising results in reducing body fat among adults, and we propose to test the efficacy of CLA supplementation on body fat accretion in 6 to 10 year old children who are overweight or at risk of overweight.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Overweight
Dietary Supplement: Conjugated linoleic acid
3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
  • Experimental: A
    Intervention: Dietary Supplement: Conjugated linoleic acid
  • Placebo Comparator: B
    Intervention: Dietary Supplement: Conjugated linoleic acid
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
62
September 2008
June 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • age 6 to 10 years
  • body mass index greater than 85th percentile
  • Tanner stage I

Exclusion Criteria:

  • medical condition
  • dairy allergy
Both
6 Years to 10 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00575991
H2006-0300
Yes
University of Wisconsin, Madison
University of Wisconsin, Madison
Loders Croklaan
Principal Investigator: Dale A Schoeller, PhD University of Wisconsin, Madison
University of Wisconsin, Madison
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP